INDV-6001 for Opioid Use Disorder

Not currently recruiting at 11 trial locations

Overseen By Eric Chavez

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Indivior Inc.

Must be taking: Buprenorphine

Must not be taking: Methadone, Naltrexone, Antiarrhythmics, others

Disqualifiers: Chronic opioid treatment, QT prolongation, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment, INDV-6001, a 3-month long-acting injectable buprenorphine, for individuals with opioid use disorder (OUD). The main goal is to understand how the body processes the drug and to determine the optimal dosing plan. Participants will first stabilize on the current medication, SUBOXONE, before transitioning to INDV-6001. The trial will also explore different injection sites, such as the thigh and the back of the upper arm. Individuals with moderate or severe OUD who are already using certain opioid treatments may be suitable candidates for this study. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

Will I have to stop taking my current medications?

Participants must not take any buprenorphine-containing products other than those provided in the study. Additionally, they should not be using medications that affect certain liver enzymes (CYP3A4 or CYP2C8) within 30 days before joining the study.

Is there any evidence suggesting that INDV-6001 is likely to be safe for humans?

Studies have shown that treatments like INDV-6001, such as monthly buprenorphine injections, are generally well-tolerated by people with opioid use disorder. These treatments help maintain sobriety by reducing cravings and withdrawal symptoms. In previous research, participants experienced some side effects, usually mild, like soreness at the injection site or mild nausea. Serious side effects were rare.

Since INDV-6001 is in Phase 2 trials, early safety data suggest it has been safe enough in earlier studies to continue testing. This phase gathers more detailed safety information. Researchers are testing INDV-6001 in different doses and closely monitoring for any negative effects. The goal is to find a balance between effectiveness and minimal side effects.

Participants switching from other buprenorphine treatments, like SUBOXONE or SUBLOCADE, might find the side effects similar to previous experiences. Overall, while some risk exists, current data supports a reasonable safety profile for INDV-6001 in treating opioid use disorder. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for opioid use disorder?

Researchers are excited about INDV-6001 for opioid use disorder because it offers a novel approach by combining Suboxone with periodic doses of INDV-6001. Unlike standard treatments, which often require daily dosing, INDV-6001 is administered in larger doses at less frequent intervals, potentially improving patient adherence and convenience. This treatment also explores different dosing schedules and combinations with Sublocade, offering flexibility and personalization in managing opioid use disorder. These unique features could lead to more effective and patient-friendly treatment options, addressing both withdrawal symptoms and long-term recovery support.

What evidence suggests that INDV-6001 might be an effective treatment for opioid use disorder?

Research has shown that high levels of buprenorphine, the main ingredient in INDV-6001, can assist individuals with opioid use disorder (OUD), particularly those using drugs like fentanyl. One study found that long-lasting buprenorphine injections support long-term recovery from OUD. The evidence confirms that these treatments are both effective and safe. INDV-6001, which participants in this trial may receive, is a new version that functions like existing buprenorphine treatments by providing steady medication levels to help manage OUD. Early results suggest this method could be promising for those dealing with opioid addiction. ^{1 6 7 8 9}

Are You a Good Fit for This Trial?

Adults aged 18-65 with moderate to severe opioid use disorder, stabilized on Suboxone or compliant with Sublocade treatment, can join this trial. They must understand and follow the study rules and agree not to take any other buprenorphine products during the trial. Women must be postmenopausal or permanently sterilized.

Inclusion Criteria

My BMI is between 18.0 and 33.0.

I have signed the consent form and can follow the study rules.

I am currently taking SUBLOCADE as prescribed, with regular 4-week injections.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pre-Investigational Medicinal Product (IMP) Period

Participants receive SUBOXONE or SUBLOCADE as part of the study until prior to the first INDV-6001 dose

Up to 4 weeks

IMP Period

Participants receive INDV-6001 from the first dose until the end of the study

Up to 260 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• INDV-6001

Trial Overview

The study tests INDV-6001's effects after multiple doses in patients with opioid use disorder. Participants will first stabilize on Suboxone or transition from a maintenance dose of Sublocade before receiving INDV-6001 at different injection sites.

How Is the Trial Designed?

Group I: Cohort 7 Experimental Treatment 3 Interventions

Participants in Cohort 7 who are new to BUP treatment will undergo rapid induction with SUBLOCADE 300 mg (per product labelling) in the abdomen on Day 1 following an initial dose of SUBOXONE (eg, 4 mg). All participants in Cohort 7 will receive: SUBLOCADE 300 mg (abdomen) on Day 1 and Day 8, SUBLOCADE 100 mg (abdomen) on Day 36, and 600mg INDV-6001 on Day 64.

Group II: Cohort 4a Experimental Treatment 1 Intervention

In Cohort 4, up to 15 participants who reach Day 120 will be enrolled in Cohort 4a. Participants in Cohort 4a will receive an injection of SUBLOCADE 100 mg (abdomen) on Day 120.

Group III: Cohort 4 Experimental Treatment 2 Interventions

SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, followed by 100 mg on Day 8, Day 36, Day 64, and Day 92)

Group IV: Cohort 3a Experimental Treatment 1 Intervention

In Cohort 3, up to 15 participants who reach Day 127 will be enrolled into Cohort 3a. Participants in Cohort 3a will receive an injection of SUBLOCADE 300 mg (abdomen) on Day 127.

Group V: Cohort 3 Experimental Treatment 2 Interventions

SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, 600 mg Day 8, followed by 250 mg on Day 15, Day 43, Day 71, and Day 99)

Group VI: Cohort 2a Experimental Treatment 1 Intervention

In Cohort 2, up to 15 participants who reach Day 232 will be enrolled into Cohort 2a. Participants in Cohort 2a will receive an additional injection of INDV-6001 600 mg in the thigh on Day 232.

Group VII: Cohort 2 Experimental Treatment 2 Interventions

SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, followed by 600 mg on Day 8, Day 64, Day 120, and Day 176)

Group VIII: Cohort 1a Experimental Treatment 1 Intervention

In Cohort 1, up to 15 participants who reach Day 260 will be enrolled into Cohort 1a. Participants in Cohort 1a will receive an additional injection of INDV-6001 600 mg in the back of the upper arm on Day 260.

Group IX: Cohort 1 Experimental Treatment 2 Interventions

SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, followed by 600 mg on Day 8, Day 92, and Day 176)

Who Is Running the Clinical Trial?

Indivior Inc.

Lead Sponsor

Trials

56

Recruited

11,400+

Published Research Related to This Trial

In 2017, only 38% of substance use treatment facilities in the U.S. offered any medication for opioid use disorder (MOUD), with 62% providing extended-release naltrexone (XR-NTX) but only 3% offering the buprenorphine implant.

The availability of XR-NTX was higher in certain regions and federally-funded facilities, particularly in states with high opioid overdose mortality rates, highlighting a need to improve access to long-acting MOUD options to better address opioid use disorder.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Predictors of availability of long-acting medication for opioid use disorder. Shover, CL., Humphreys, K.[2020]

In a study involving 570 adults with opioid use disorder, buprenorphine-naloxone was found to be more cost-effective than extended-release naltrexone, being preferred in 97% of cases at 24 weeks and 85% at 36 weeks based on quality-adjusted life-years (QALYs).

The analysis suggests that buprenorphine-naloxone is the better first-line treatment option, especially for patients needing detoxification before starting extended-release naltrexone, although the study had limitations such as a relatively short follow-up period.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse. Murphy, SM., McCollister, KE., Leff, JA., et al.[2020]

New prolonged-release formulations of buprenorphine, including a six-month implant and two subcutaneous injection depots, aim to improve patient comfort and safety by reducing the need for daily intake and minimizing risks associated with sublingual forms.

These formulations have shown promise in addressing concerns about treatment adherence, particularly for stabilized patients, while also raising some apprehensions about potential coercive use among opioid users.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Prolonged-release buprenorphine formulations: Perspectives for clinical practice]. Chappuy, M., Trojak, B., Nubukpo, P., et al.[2022]

Methadone and buprenorphine are effective first-line treatments for opioid dependence, with new long-acting formulations like CAM 2038 (Buvidal®), RBP-6000 (Sublocade™), and Probuphine™ offering innovative options for maintenance therapy.

These long-acting buprenorphine formulations provide flexibility in treatment schedules, potentially improving adherence and outcomes for individuals with opioid dependence.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[New slow-release buprenorphine formulations for optimization of opioid substitution]. Soyka, M., Pogarell, O.[2020]

New prolonged-release formulations of buprenorphine, including a six-month implant and two subcutaneous injection depots, aim to improve patient comfort and safety by reducing the need for daily intake and minimizing risks associated with sublingual forms.

These formulations have shown promise in addressing concerns about treatment adherence, particularly for stabilized patients, while also raising some apprehensions about potential coercive use among opioid users.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Prolonged-release buprenorphine formulations: Perspectives for clinical practice. Chappuy, M., Trojak, B., Nubukpo, P., et al.[2021]

Long-acting buprenorphine formulations, including CAM 2038 (Buvidal), RBP-6000 (Sublocade™), and Probuphine™, provide effective options for treating opioid use disorders (OUDs) with varying administration schedules, such as weekly, monthly, or every six months.

These depot and implant formulations enhance patient adherence to treatment by reducing the frequency of dosing compared to traditional oral or sublingual medications, potentially improving overall outcomes in managing OUDs.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations. Soyka, M., Franke, AG.[2021]

Citations

1.

indivior.com

indivior.com/en/media/press-releases/indivior-presents-new-data-at-cpdd-demonstrating-that-high-buprenorphine-exposure-may-improve-treatment-outcomes-in-high-fentanyl-users

Indivior Presents New Data at CPDD Demonstrating that ...

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users.

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12125644/

Initiating Injectable Buprenorphine in People Hospitalized ...

This randomized clinical trial of patients with opioid use disorder (OUD) hospitalized for infection examines whether initiating long-acting buprenorphine plus ...

3.

firstwordpharma.com

firstwordpharma.com/story/5478741

Alar Announces Significant Progress on Developing Long- ...

Based on the data of safety assessments, subcutaneous injections of ALA-1000 were well-tolerated in all dose-escalation cohorts. All the drug- ...

4.

prnewswire.com

prnewswire.com/news-releases/indivior-highlights-growing-body-of-data-on-sublocade-buprenorphine-once-monthly-extended-release-injection-helping-patients-achieve-long-term-recovery-from-opioid-use-disorder-during-substance-abuse-prevention-month-302291790.html

Indivior Highlights Growing Body of Data on SUBLOCADE ...

Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe.

5.

indivior.com

indivior.com/resources/dam/id/1785/Master%20Indivior%20Investor%20Presentation%20July%202025%20vF.pdf

Investor Presentation

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine. Treatment: 12-Month Longitudinal Outcomes From RECOVER, an ...

6.

ctv.veeva.com

ctv.veeva.com/study/indv-6001-multiple-dose-pharmacokinetic-study

INDV-6001 Multiple-Dose Pharmacokinetic Study

The current study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD.

7.

reporter.nih.gov

reporter.nih.gov/project-details/10682808

Injectable 3-month buprenorphine PLGA microparticle ...

This project aims to develop an injectable 3-month buprenorphine PLGA microparticle formulation. Each formulation will contain 300 mg buprenorphine for ...

8.

jamanetwork.com

jamanetwork.com/journals/jamanetworkopen/fullarticle/2834656

Initiating Injectable Buprenorphine in People Hospitalized ...

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo ...

9.

cdek.pharmacy.purdue.edu

cdek.pharmacy.purdue.edu/trial/NCT06576843/

Trial | NCT06576843

The current study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD to select ...